Shoulder Innovations, which has developed advanced implant systems for shoulder arthroplasty, filed with the SEC to raise up to $100 million in an initial public offering. No pricing terms were disclosed.
Shoulder Innovations offers implant systems as well as enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration.
Net proceeds will support the scale-up of commercial organization through the hiring of additional sales representatives and expansion of the commercial leadership team, as well as investment in additional instrument sets to support volume growth and geographic expansion; research and development of continued general innovation in the company’s implant systems; and working capital and other general corporate purposes.
The company was founded in 2009 and posted $35 million in revenue for the 12 months ended March 31, 2025. It plans to list on the NYSE under the symbol SI. As of March 31, 2025, SI has sold 1,443 implant systems, up from 559 as March 31, 2023.
Shoulder Innovations, which has developed advanced implant systems for shoulder arthroplasty, filed with the SEC to raise up to $100 million in an initial public offering. No pricing terms were disclosed.
Shoulder Innovations offers implant systems as well as enabling technologies, instrument systems, specialized support and surgeon-to-surgeon...
Shoulder Innovations, which has developed advanced implant systems for shoulder arthroplasty, filed with the SEC to raise up to $100 million in an initial public offering. No pricing terms were disclosed.
Shoulder Innovations offers implant systems as well as enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration.
Net proceeds will support the scale-up of commercial organization through the hiring of additional sales representatives and expansion of the commercial leadership team, as well as investment in additional instrument sets to support volume growth and geographic expansion; research and development of continued general innovation in the company’s implant systems; and working capital and other general corporate purposes.
The company was founded in 2009 and posted $35 million in revenue for the 12 months ended March 31, 2025. It plans to list on the NYSE under the symbol SI. As of March 31, 2025, SI has sold 1,443 implant systems, up from 559 as March 31, 2023.
Copy to clipboard 
